Incidence of Lacrimal and Salivary Gland Dysfunction in 79 Patients After Radioiodine Therapy
| First year n (%) | Second year n (%) | Third year n (%) | |
|---|---|---|---|
| Subjective xerostomia | 26 (32.9%) | 16 (20.3%) | 12 (15.2%) |
| New cases* | 2 | ||
| Objective xerostomia | 40 (50.6%) | 11 (13.9%) | 11 (13.9%) |
| Stage 2 | 24 | 6 | 6 |
| Stage 3 | 16 | 5 | 5 |
| Stage 4 | — | — | — |
| New cases* | 3 (3.8%) | 28 (35.4%) | |
| Stage 2 | 3 | 23 | |
| Stage 3 | — | 5 | |
| Stage 4 | — | — | |
| Subjective xerophthalmia | 20 (25.3%) | 14 (17.7%) | 11 (13.9%) |
| New cases* | 1 | ||
| Objective xerophthalmia | 14 (17.7%) | 11 (13.9%) | 6 (7.6%) |
| Schirmer test | 14 | 11 | 6 |
| Rose Bengal dye | 8 | 3 | 3 |
| Tear break-up time | 10 | 8 | 4 |
| New cases* | 2 (2.5%) | 2 (2.5%) | |
| Shirmer test | 2 | 2 | |
| Rose Bengal dye | 1 | 2 | |
| Tear break-up time | 1 | 1 |
↵* New cases: cases detected during the second or third year of follow-up.
Salivary gland scintigraphy dysfunction stages: 1, normal uptake and excretion; 2, mild dysfunction; 3, moderate dysfunction; and 4, severe dysfunction.